U.S. markets close in 5 hours 43 minutes
  • S&P 500

    4,407.76
    -11.39 (-0.26%)
     
  • Dow 30

    35,065.83
    -18.70 (-0.05%)
     
  • Nasdaq

    14,709.24
    -69.03 (-0.47%)
     
  • Russell 2000

    2,249.40
    +9.38 (+0.42%)
     
  • Crude Oil

    73.83
    +0.21 (+0.29%)
     
  • Gold

    1,828.80
    -7.00 (-0.38%)
     
  • Silver

    25.62
    -0.16 (-0.61%)
     
  • EUR/USD

    1.1882
    -0.0014 (-0.12%)
     
  • 10-Yr Bond

    1.2420
    -0.0270 (-2.13%)
     
  • GBP/USD

    1.3942
    -0.0016 (-0.11%)
     
  • USD/JPY

    109.7040
    +0.2430 (+0.22%)
     
  • BTC-USD

    39,076.33
    -868.68 (-2.17%)
     
  • CMC Crypto 200

    927.63
    -22.27 (-2.34%)
     
  • FTSE 100

    7,052.02
    -26.40 (-0.37%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference

·1 min read

BURLINGTON, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James Human Health Innovation Conference. The virtual fireside chat is scheduled to begin at 3:20 p.m. ET on Monday, June 21, 2021.

To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com.

About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun. Please visit flexiontherapeutics.com.

Contact:

Scott Young
Vice President, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com